STTK Graph | Shattuck Labs, Inc.

STTK Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $0.00; Research and development $11.70M; Operating expenses $16.16M; Net income -$15.15M.
2026-03-31: Revenue $0.00; Research and development $10.95M; Operating expenses $15.54M; Net income -$14.77M.
2025-12-31: Revenue $0.00*; Research and development $9.05M*; Operating expenses $13.37M*; Net income -$12.59M*.
2025-09-30: Revenue $1.00M; Research and development $7.62M; Operating expenses $11.72M; Net income -$10.06M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$0.00	$11.70M	$16.16M	-$15.15M
2026-03-31	$0.00	$10.95M	$15.54M	-$14.77M
2025-12-31	$0.00*	$9.05M*	$13.37M*	-$12.59M*
2025-09-30	$1.00M	$7.62M	$11.72M	-$10.06M
2025-06-30	$0.00	$8.68M	$13.03M	-$12.46M
2025-03-31	$0.00	$9.92M	$14.39M	-$13.70M
2024-09-30	$3.00M	$16.31M	$20.92M	-$16.68M
2024-06-30	$1.61M	$19.24M	$24.57M	-$21.55M
2024-03-31	$1.11M	$16.26M	$21.16M	-$18.50M
2023-09-30	$686.00K	$24.21M	$29.28M	-$27.54M
2023-06-30	$200.00K	$18.20M	$22.95M	-$21.35M
2023-03-31	$57.00K	$16.67M	$21.72M	-$20.72M
2022-09-30	$212.00K	$18.86M	$25.44M	-$24.64M
2022-06-30	$50.00K	$22.96M	$27.71M	-$27.37M
2022-03-31	$0.00	$19.19M	$24.17M	-$24.53M
2021-09-30	$1.90M	$15.14M	$19.48M	-$17.41M
2021-06-30	-$4.23M	$14.88M	$20.28M	-$23.60M
2021-03-31	$2.27M	$10.34M	$14.69M	-$11.81M
2020-09-30	$2.44M	$11.80M	$14.27M	-$11.83M
2020-06-30	$3.18M	$7.75M	$9.50M	-$6.21M
2020-03-31	$2.98M	$8.14M	$9.74M	-$6.55M
2019-09-30	$1.78M	$7.95M	$9.31M	-$7.28M
2019-06-30	(m)	(m)	(m)	-$5.88M
2019-03-31	(m)	(m)	(m)	-$3.45M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$0.00	$22.65M	$31.70M	-$29.92M
2025-06-30	$0.00	$18.60M	$27.42M	-$26.16M
2024-06-30	$2.72M	$35.50M	$45.73M	-$40.06M
2023-06-30	$257.00K	$34.87M	$44.66M	-$42.07M
2022-06-30	$50.00K	$42.15M	$51.87M	-$51.90M
2021-06-30	-$1.96M	$25.22M	$34.97M	-$35.41M
2020-06-30	$6.16M	$15.89M	$19.24M	-$12.76M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Net income
2025-09-30	$1.00M	$26.22M	$39.14M	-$36.22M
2024-09-30	$5.72M	$51.82M	$66.65M	-$56.73M
2023-09-30	$943.00K	$59.08M	$73.95M	-$69.61M
2022-09-30	$262.00K	$61.01M	$77.31M	-$76.53M
2021-09-30	-$61.00K	$40.36M	$54.45M	-$52.82M
2020-09-30	$8.59M	$27.70M	$33.51M	-$24.59M
2019-09-30	$7.07M	$20.45M	$24.51M	-$16.61M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$1.00M	$35.27M	$52.51M	$0.00	-$48.81M
2024-12-31	$5.72M	$67.21M	$86.29M	$0.00	-$75.41M
2023-12-31	$1.66M	$74.31M	$93.61M	$0.00	-$87.30M
2022-12-31	$652.00K	$82.90M	$103.98M	$0.00	-$101.94M
2021-12-31	$30.02M	$56.56M	$75.29M	$0.00	-$44.97M
2020-12-31	$9.93M	$37.48M	$46.87M	$0.00	-$36.60M
2019-12-31	$9.89M	$29.22M	$34.95M	$0.00	-$23.98M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Neurogene Inc. (NGNE)		$0.625B	-4.46
BlossomHill Therapeutics, Inc. (BLSM)	United States	$0.647B
IMPACT BIOMEDICAL INC. (IBO)	United States	$0.611B	66.47
Aquestive Therapeutics, Inc. (AQST)	United States	$0.606B	-6.67
CorMedix Inc. (CRMD)	United States	$0.605B	3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)	United States	$0.668B	14.61
CytomX Therapeutics, Inc. (CTMX)	United States	$0.598B	-10.25
Monopar Therapeutics (MNPR)	United States	$0.598B	-34.82
Altimmune, Inc. (ALT)	United States	$0.593B	-6.43
Climb Bio, Inc. (CLYM)	United States	$0.683B	-13.03